Introduction
A recent long-template, high-fidelity PCR study on the fine structure of the T(12;15) translocation in primary pristaneinduced peritoneal BALB/c plasmacytomas demonstrated that five tumors that harbored plasmacytoma-typical rearrangements between c-myc and the upstream flank of C␣ (5Ј-C␣) were in fact derived from precursors that contained rearrangements between c-myc and the upstream flank of C (5Ј-C). 1 This finding provided strong evidence that, in these five tumors, the T(12;15) translocations originated by illegitimate 5Ј-C/c-myc recombinations, which were subsequently altered or 'remodeled' into derivative 5Ј-C␣/c-myc recombinations by isotype switch-like deletions that took place on the c-myc-deregulating product of translocation, Chr T(12;15). The 5Ј-C/c-myc to 5Ј-C␣/c-myc conversion was of considerable interest for pathogenetic concepts on plasmacytomagenesis because it suggested that the 5Ј-C/c-myc rearranged cell was the most probable candidate for the thus far elusive plasmacytoma precursor. It further suggested that 5Ј-C/c-myc + cells were capable of expanding into clones from which progenitors could be selected for plasmacytoma progression. However, our attempts to detect 5Ј-C/c-myc + cell clones in plasmacytoma-susceptible BALB/c mice were largely unsuccessful in spite of employing sensitive PCR methods that had been shown to detect reliably rearrangements between 5Ј-C and c-myc. In untreated BALB/c mice, 5Ј-C/c-myc rearranged clones were not found. In pristane-treated BALB/c mice, such clones were uncovered sporadically in pristaneinduced inflammatory granulomata, but never in lymphoid tissues. These observations, which suggested that 5Ј-C/cmyc + clones are scarce in strain BALB/c, caused us to turn our attention to IL-6 transgenic/congenic BALB/c mice (BALB/c.IL-6 mice). Predicting that IL-6, a growth and survival factor for normal B cells, may also be important for abnormal 5Ј-C/cmyc rearranged cells, we postulated that BALB/c.IL-6 mice may be more competent in promoting the growth and/or survival of 5Ј-C/c-myc + clones than conventional BALB/c mice. In addition, we anticipated that the ubiquitous presence of IL-6 in the transgenic mice may be able to liberate the 5Ј-C/cmyc + cells from the dependence on the inflammatory granuloma, a significant source of IL-6 in pristane-treated BALB/c mice, and permit these cells to develop in lymphoid tissues instead. Here, we show that these predictions were correct and that 48% of untreated BALB/c.IL-6 mice contained 5Ј-C/c-myc + clones in their lymph nodes and Peyer's patches. This finding associated the ability of IL-6 to facilitate plasmacytoma development for the first time with a specific target cell for plasmacytomagenesis, the 5Ј-C/c-myc + plasmacytoma precursor, and suggested that IL-6 plays a significant role in the early stage of plasmacytoma development.
Materials and methods

Mice and tissue samples
BALB/cAnPt.C57BL/6J.H-2L
D -hu-IL-6 mice, hereafter called BALB/c.IL-6, were derived from C57BL/6J.H-2L D -hu-IL-6 mice, which were developed by Tadamitsu Kishimoto and his associates. 2 The C57BL/6 derived IL-6 transgene was introduced on to BALB/cAnPt by Michael Potter (Laboratory of Genetics, NCI, NIH), who performed the introgressive backcrossing. The backcross is still ongoing and currently in its 17th generation (N17). The mice used in the experiment here originated from the 12th to 15th backcross (N12-15) and included both males and females that ranged in age from 4 to 10 months. The mice were bred and maintained in our new conventional facility on the NIH campus. They were not treated with pristane (2,6,10,14-tetramethylpentadecane), a widely used agent for the induction of plasmacytomas in conventional BALB/c mice. IL-6 transgenic BALB/c mice develop, just like the parental C57BL/6 mice, striking accumulations of plasma cells in their up to 10-fold enlarged lymph nodes, splenomegaly, glomerulonephritis, and other pathologies of 'IL-6 disease' beginning at 3 to 4 months of age. The enlargement of peripheral lymph nodes, which usually appears first at 3 months of age, is convenient for establishing the diagnosis of IL-6 disease by simple visual inspection of mice hanging down by their tails. The mice with apparent IL-6 disease were euthanisized according to NIH guidelines and the peripheral lymph nodes (inguinal, brachial, axillary, cervical), central lymph nodes (mesenteric, abdominal, pararenal, perithymic) and Peyer's patches were obtained for PCR analysis.
PCR methods and primers
For the preparation of high molecular weight DNA, tissues were processed with a standard phenol/chloroform extraction protocol that included digestion with proteinase K (100 g/ml; Boehringer Mannheim, Indianapolis, IN, USA) and RNAse A (40 g/ml; Sigma, St Louis, MO, USA). Long-template and high-fidelity PCR kits (Boehringer Mannheim) were employed on 500 ng aliquots of genomic DNA to detect junctional fragments between the upstream flanks of immunoglobulin heavychain genes (5Ј-CH) and c-myc, the molecular indications of T(12;15) translocations. Hot-start two-round amplifications with nested primer pairs (Table 1) were performed with the following cycling conditions; initial denaturation at 96°C for 5 min with the reaction subsequently being held at 80°C for the addition of polymerase mix (1.75 units per 50 l reaction). This was followed by 25 cycles of template denaturation at 95°C for 15 s, primer annealing at 62°C for 15 s, and primer extension at 68°C for 4 to 7 min in the first cycle with a progressive prolongation of the extension time by 20 s for each of the subsequent cycles. Final extension times amounted to 11.5-14.5 min. For the second round of PCR, 1 to 5 l of reaction mixture from round one was used with nested primer pairs for an additional round of 25 cycles. The concentration of dNTPs (200 mM) and Mg 2+ (1.5-1.75 mM final) were the same in both rounds of PCR.
Sensitivity of PCR
To determine the sensitivity of the PCR for detecting T(12;15)-typical translocation fragments between 5Ј-C and c-myc, serial dilution and co-amplification experiments were performed with model templates (tumor DNAs) similar to previously described experiments, in which unique CH primers, 3 switch consensus primers, 4 or hybridization-enriched templates with both unique CH primers and switch consensus primers 5 were used to determine the detection limits of T(12;15)-typical junction fragments between 5Ј-C␣ and c-myc. Genomic DNAs obtained from the plasmacytomas TEPC 1194, TEPC 3609, and TEPC 3610 were used as clonal model templates for PCR amplification. These tumors have been shown in previous studies to contain 5Ј-C/c-myc rearrangements, and their structure has been fully analyzed. 1, 6 Tumor DNAs were serially diluted (individually or combinatorially) into liver or kidney DNA to simulate the presence of 5Ј-C/c-myc + clones at decreasing abundancy in normal tissues. When one-round PCR amplifications of 500 ng aliquots of these DNA mixtures (corresponding to a total of ෂ2 × 10 5 cells) were performed in quadruplicates, it was found that approximately 2.5 ng of tumor DNA (corresponding to ෂ1000 tumor cells) had to be present to reliably generate the expected PCR products in all four reactions. The sensitivity of two-round PCR with nested primer pairs was naturally higher and approached approximately 20 tumor cells among a total of 2 × 10 5 cells; ie 20 tumor cells were detected in all four reactions when the experiments were performed in quadruplicate. The reproducibility of the PCR deteriorated rapidly at lower copy numbers of 5Ј-C/c-myc rearrangements and resulted in the failure to reliably detect the expected PCR product in quadruplicates. This was particularly evident in co-amplification experiments with two or three templates, which were performed with identical (low) copy numbers of templates, but resulted in the detection of only one or two PCR products instead of the expected two or three products. Taken together, our results suggested that clones of 5Ј-C/c-myc + B cells had to be (at least moderately) expanded (ෂ50-100 tumor cells per 500 ng DNA tissue sample) in order to permit reproducible PCR detection in quadruplicates.
Histology and immunostaining
For histology, lymph nodes and Peyer's patches were fixed in a mixture of 70% ethanol/formalin/glacial acetic acid (20/2/1, v/v/v), transferred to 70% ethanol and embedded in paraffin. Four m-thick sections were stained with hematoxylin and eosin (American Histo Labs, Gaithersburg, MD, USA) in order to assess the infiltration of the lymphoid tissues with plasma cells. Additional sections were stained with Giemsa according to Lennert, PAS, and methyl green and pyronine to distinguish normal from atypical plasma cells. Silver staining according to Gomori was used to visualize reticular fibers. For the immunohistochemical determination of Ig production by plasma cells, tissue sections were stained with a combined avidinbiotin immunoperoxidase technique. Antisera to lightchains and , ␥ and ␣ heavy-chains were used as the primary reagents for immunostaining (Southern Biotechnology Associates, Birmingham, AL, USA). No attempt was made to distinguish the four ␥ isotypes, and a pooled ␥ antiserum was used instead to estimate the relative abundance of IgG secreting plasma cells in relation to IgA or IgM producing plasma cells. Sections were counterstained with hematoxylin and lithium chloride and evaluated with an Olympus light microscope.
Results
Detection of 5Ј-C/c-myc exchanges by PCR
Direct PCR with nested primer pairs was employed to detect 2-10 kb long junction fragments of balanced genetic recombinations that juxtaposed c-myc to the 5Ј flank of C. The unique, clonotypic 5Ј-C/c-myc junctions were used as the molecular indicators of aberrant clones that harbored T(12;15) translocations. Only clones for which both products of translocations had been detected were included in this study. That is, additional 5Ј-C/c-myc junctions that were found to be copresent in the tissue sample but unmatched by a reciprocal junction fragment were excluded. A total of 14 junction fragments indicative of Chr T(12;15) were discarded for this reason. Although this stringent self-imposed rule resulted in the likely underestimation of the true prevalence of 5Ј-C/c-myc + clones in BALB/c.IL-6 mice, it was adhered to for three reasons. First, the reproducible detection of both products of translocation in the same tissue added confidence to our intention to focus exclusively on 'expanded' clones rather than microclones or individual translocated cells (cf. last paragraph in the Materials and methods section). Second, the accurate fine-structural analysis of both products of translocation was the precondition for determining deletions and duplications that may have occured in 5Ј-C and/or c-myc during the genetic exchange. This information was valuable because it provided clues for the mechanism of translocation. Third, although the structure of Chr T(12;15) was of primary interest for molecular analysis (it harbored the deregulated cmyc gene), the structure of Chr T(15;12), the reciprocal product of translocation, was also of interest because it contained clonotypic DJ or VDJ rearrangements that were helpful for differentiating among various T(15;12)
+ clones co-present in the same tissue.
Prevalence of clones containing 5Ј-C/c-myc recombinations
A total of 25 untreated BALB/c.IL-6 mice were included in this study. Nine mice harbored one 5Ј-C/c-myc + clone and three mice contained two such clones. Thus, 12 out of 25 (48%) BALB/c.IL-6 mice were found to be positive. Of the 15 translocated clones that were completely analyzed, five resided in Leukemia the mesenteric node, three in Peyer's patches, and seven in peripheral lymph nodes. The observation suggested that the clones were evenly distributed throughout the lymphoid system, although more mice should be studied and additional lymph nodes included before this can be decided definitively. Histological analysis indicated that the lymph nodes in which the aberrant clones resided consisted predominantly of plasma cells (see Figure 1 for a representative example), similar to the pronounced plasmacytosis observed by Ohno et al 7 in lymph nodes of IL-6 transgenic BALB/c N6 mice carrying a Robertsonian marker chromosome. The virtually monomorphic infiltration of many lymph nodes and Peyer's patches with plasma cells seemed to be most compatible with the proposition that the 5Ј-C/c-myc + clones were of plasmacytic nature. Most of the plasma cells were small like those seen in other types of plasma cell hyperplasias; yet, clusters of enlarged and hyperchromatic plasma cells were also observed on some occasions, suggesting that plasmacytomas may develop in situ (results not shown). However, this possibility will have to be tested in transplantation experiments, because the distinction between plasmacytosis and plasmacytoma is probably ambiguous when solely based on morphological criteria.
Fine structure of 5Ј-C/c-myc recombinations
The 5Ј-C/c-myc + clones were characterized by DNA sequence analysis in order to determine the recombinational breakpoints in 5Ј-C and c-myc and the flanking sequences ( Table 2 ). All 5Ј-C/c-myc junctions were found to be unique (clonotypic). Figure 2 shows that the breakpoints in c-myc seemed to be concentrated around the boundary between exon 1 and intron 1. A total of 11 out of 15 breakpoints were found in an approximately 300 bp long cluster on Chr T(12;15)-typical fragments, including 8198 at the 5Ј most end and 7841 at the 3Ј most end (see horizontal line below the map of c-myc in Figure 2) . A similar 400-bp cluster common to most breaksites on Chr T(15;12)-typical fragments contained 12 breakpoints, including 8198 at the upstream end and 8081 at the most downstream end (see horizontal line above the map of c-myc). The exon 1/intron 1 boundary of cmyc was thus the preferred breakpoint region in c-myc on both products of translocation. The translocation breakpoint in clone 7936 was exceptional because it occurred in the 5Ј flank of c-myc. This resulted in the allocation of exon 1, which contains the two major c-myc promoters, P1 and P2, to Chr T(12;15), the c-myc-deregulating product of translocation. Plasmacytomas with a disruption of c-myc in its upstream flank belong to the rare class II of tumors according to Cory; 8 they are unusual in terms of transcriptional regulation of c-myc. 9 In the 5Ј-C region, all but one of the Chr T(12;15)-typical breaksites were found in S. Seven breaksites ranging from 7910-2 to 8185 occurred in the distal half of S; one break, 8149-1, was found in the proximal half of S. Six breakpoints could not be determined accurately because they occurred within a stretch of tandem pentameric repeats embedded in highly rearranged S regions (see breaksites indicated by a hyphen below the map of 5Ј-C). The single breakpoint, 7904, that occurred outside of S was exceptional because it resulted in the allocation of the intronic heavy-chain enhancer, E, to the c-myc gene on Chr T(12;15). The juxtaposition of E to c-myc is unusual for BALB/c plasmacytomas, yet has been observed in one tumor. 10 Adams and co- workers 11 demonstrated that the E/c-myc fragment obtained from this tumor is highly tumorigenic and able to induce pre-B lymphomas upon transgenic expression. Most Chr T(15;12)-typical breaksites were found in an approximately 1 kbp long region that consisted of the 5Ј half of S and its immediate upstream flank. Ten of 15 breakpoints ranging from 8198 to 7936 were observed in this region (see horizontal line above the map of 5Ј-C in Figure 2 ), which coincides with the region where many normal isotype switch recombinations have been reported to occur. 12 It is noted on conjecture that the fine structure of the 5Ј-C/c-myc exchanges found in the mouse was virtually indistinguishable from the molecular structure of c-myc-activating recombinations that take the form of balanced T(8;14) translocations in human malignancies, eg in sporadic Burkitt's lymphomas and AIDS-associated B cell lymphomas. 13 
Mechanism of the 5Ј-C/c-myc exchange
While the mechanism of the 5Ј-C/c-myc exchange and the nature of the cell in which this recombination occurs are not completely established, it seems reasonable to postulate that the recombination event takes place in a mature B cell that is in the process of isotype switching. Isotype switch recombination necessitates the introduction of a DNA double-strand break in the donor region for recombination, S. If the break in S occurred in a B cell that also harbored an interrupted c-myc gene in close proximity to the Ig heavy-chain gene cluster; ie in the same nuclear sector, then the two broken chromosomes could be joined illegitimately to create the T(12;15) chromosomal translocation. The observation that the 5Ј-C/cmyc exchanges were accompanied invariably by large deletions in S was consistent with this hypothesis, since S deletions are common in B cells undergoing isotype switching. 14, 15 Furthermore, the average length of deletions in S was 2.7 kb and thus considerably longer than the average deletion in c-myc, which was just 171 bp (calculated from Table 2 , last two columns). This suggested that S was targeted by a deletional mechanism (switch recombinase?) that was not acting on c-myc, or that S was more affected by the said mechanism if it involved both loci. The finding that 12 of 15 (80%) breaksites in c-myc clustered in a narrow region that spanned the exon 1/intron 1 boundary of the gene, a 300-bp cluster on Chr T(12;15) and a 400-bp cluster on Chr T(15;12), was also compatible with the postulate that class switching triggered the trans-chromosomal exchange, since this region contained an unusual prevalence of S pentamers. A short 97-bp region in the center of the breakpoint cluster was found to contain four S-typical GGGGT repeats (only one motif would be expected to occur randomly in a 1024-bp stretch of DNA). Additional studies are warranted to determine if switch repeats, other recombinational motifs, or entirely different sequence features like bent DNA, 16 may facilitate the alignment of c-myc with S prior to the translocation event. Likewise, experiments should be designed to test the possibility that IL-6 plays a direct role in the generation of S/c-myc exchanges, eg by inducing isotype switching 17 and thus DNA double-strand breakage in S, or by activating transcription of c-myc, 18 which may also be recombinogenic by keeping the gene in the 'open' chromatin configuration that is thought to be more susceptible to endonucleolytic attack and introduction of DNA breaks.
Co-existence of c-myc rearranged clones that utilized CH loci different from C
PCR methods for detecting exchanges between c-myc and the upstream flanks of the CH loci distal of C were employed to gain insights into the clonal diversity of T(12;15)
+ clones that d Recombination breaksites were blunt ended (hyphen), occurred with nucleotides that could have been derived from either 5ЈC or cmyc (thus denoting homologies at the breaksite; lower case), or contained nucleotides that could not be accounted for in the germline of 5Ј-C and c-myc (upper case).
e Deletions of S in base pairs. Size of deletions were calculated by subtracting the length of the PCR product from the length of the germline region. Deletions were accurately determined in most cases (PCR fragments were completely sequenced), but were estimated in four cases (7854-1, 7895, 8191, 8198) in which the rearranged S region was not completely sequenced. In these cases, the estimates were based on the length of the PCR products, which was determined with the help of DNA size markers on high-resolution agarose gels. f Deletions in c-myc in base pairs. In two cases, 7910-1 and 8081, duplications were found. g The deletion at the cross-over site in the 5Ј flank of E amounted to just 14 bp; however, it was accompanied by an approximately 1 kb long deletion in S on the Chr T(12;15)-typical junction fragment.
resided in the same mouse or tissue. All CH genes downstream of C, except C␦ for which dedicated PCR methods have not been developed, were included in the analysis. A total of 20 clones that harbored rearrangements between cmyc and the 5Ј flank of C␥1, C␥2b, C⑀ and C␣ were found ( Table 3 (Table 3 , line 7) in addition to the single 5Ј-C/c-myc + clone (see Table 2 , line Leukemia 13). This result indicated that secondary lymphoid tissues of IL-6 transgenic BALB/c mice are in principal capable of promoting mosaics of translocated clones.
Discussion
The main finding described in this paper is the striking ability of IL-6 transgenic BALB/c mice to promote T(12;15) translocated clones that harbored in their translocation breakpoint region plasmacytoma precursor-typical illegitimate genetic rearrangements between the upstream flank of C (5Ј-C) and the proto-oncogene c-myc (5Ј-C/c-myc + clones). A total of 15 5Ј-C/c-myc + clones were found in hyperplastic lymphoid tissues of 12 out of 25 (48%) untreated BALB/c mice carrying a human IL-6 transgene under the transcriptional control of the histocompatibility H-2L D promoter (BALB/c.IL-6 mice). Similar clones were also detected in the granulomatous inflammatory tissues of pristane-treated BALB/c mice (not transgenic for IL-6), albeit at a considerably lower frequency, three of 23 mice (13%). The occurrence of the clones in the pristane-induced peritoneal granuloma is of particular interest, since this tissue is a significant source of IL-6 in vivo 19, 20 and also the site where plasmacytomas develop. Map of breakpoints in c-myc and 5Ј-C. A schema of the upstream region of the c-myc gene is shown at the top. It consists of exon 1 with its near 5Ј flank and most of intron 1. The two major c-myc promoters, P1 and P2, and the recently identified Stat3 binding site, which is located between the promoters in a region that overlaps with the E2F site, 18 are depicted by labeled triangles and an asterisk, respectively. A schema of the 5Ј flank of the C gene, which spans the joining gene region (JH) and the first exon of C, is depicted at the bottom. The intronic heavy-chain enhancer, the 3.5 kbp long, highly repetitive S region and exon 1 of C are illustrated by boxes labeled E, S and C 1, respectively. The intervening region between E and S is designated 5Ј-S. The four functional joining gene segments, J1 to J4, and the single J pseudogene are labeled. Annealing sites for PCR primer pairs are shown by horizontal arrowheads (cf. Table 1 ). Sites at which recombinations occurred (cf. Table 2 ) are indicated by vertical arrows: breaksites of head-to-head recombinations indicative of Chr T(12;15) are depicted below the maps of c-myc and 5Ј-C pointing up; breaksites of tail-to-tail recombinations typical for Chr T(15;12) are indicated above the maps pointing down. Most breakpoints in c-myc and most Chr T(15;12)-typical breakpoints in 5Ј-C are spread out on horizontal helper lines because they were too crowded to show them with individual arrows. All breaksites in c-myc were determined accurately, the precondition for measuring the deletions and duplications that occurred in the gene in result of recombination (see Table 2 , last column). In 5Ј-C, the position of the Chr T(15;12)-typical breaksite in sample 7895 could not be located precisely because it occurred in a monotonous stretch of tandem pentameric S repeats that were flanked by internal deletions. This is indicated by a question mark. Furthermore, the Chr T(12;15)-typical breaksites of samples 6960, 7841, 7854-1, 7895, 8191 and 8198 were not determined accurately (in spite of complete DNA sequence analyses of breakpoint regions), since they occurred in highly rearranged S regions that permitted only a patchy alignment with the germline or no alignment at all. This is indicated by a labeled hyphen pointing up.
Table 3
Occurrence of 5Ј-CH/c-myc clones in lymphoid tissues of untreated BALB/c.IL-6 mice Table 2 ) and 5Ј-CH/c-myc + clones. b The type of clone and the tissue where it was found, separated by a backslash. The type of clone was defined by the recombinational partner of c-myc, which included the upstream flanks of C␥1, C␥2b, C⑀ and C␣. The tissues in which 5Ј-CH/c-myc clones resided included mesenteric (m), cervical (c), and axillary (a) lymph nodes (LN), Peyer's patches (PP), and spleen (Sp). c Mice contained 5Ј-CH/c-myc + clones, but no 5Ј-C/c-myc + clones. d Clone was co-present in three Peyer's patches. e Clone was co-present in four Peyer's patches. f Clone was co-present in two Peyer's patches.
hypothesis that the levels of IL-6 produced in the granulomata may in most mice be insufficient for promoting the aberrant cells, or that the production of IL-6 may be discontinuous and therefore accompanied by the demise of all clones that are susceptible to its temporal withdrawal. Although this has not been demonstrated, the fluctuation of IL-6 levels in vivo seems to offer an attractive explanation for both the incomplete penetrance of plasmacytomagenesis in pristane-treated BALB/c mice (generally not exceeding 65% on day 300 after the first i.p. injection of pristane) and the inhibition of tumor development by anti-inflammatory agents 22 or changes in the environment (eg diminished exposure to antigens). 23 The apparent promotion of 5Ј-C/c-myc + clones in IL-6 transgenic BALB/c mice can be added to the body of evidence on the significance of IL-6 for plasmacytomagenesis in conventional BALB/c mice. [24] [25] [26] Furthermore, the finding that BALB/c mice homozygous for an IL-6-null allele (BALB/c.IL-6 −/− ) were completely resistant to plasmacytomagenesis induced by the pristane 27 and the Myc and Raf expressing retrovirus, J3V1, 28 established that IL-6 plays a unique and requisite role in both inflammation-induced and virally induced plasmacytoma development. Subsequent studies with another retrovirus that constitutively co-expressed Abl and Myc revealed an important mechanism by which IL-6 facilitates plasmacytomagenesis, the cooperation with Myc. The tumorigenic potency of the Abl/Myc virus, 29 which is unique with regard to plasmacytomagenesis in three ways, will be briefly discussed because of its relevance for the findings in BALB/c.IL-6 mice reported here. First, the Abl/Myc virus is capable of inducing plasmacytomas in BALB/c mice with a complete penetrance (100% incidence). Second, it does not require pre-treatment (priming) with pristane, ie Abl/Mycinduced plasmacytomas can develop independently from the artificial microenvironment of the inflammatory granuloma. Indeed, some tumors have been reported to originate in lymph nodes, 30 the tissues where the 5Ј-C/c-myc + clones were found in the IL-6 transgenic BALB/c mice. Third, the Abl/Myc virus is the only plasmacytomagenic agent that has been demonstrated to override the apparent block of plasmacytoma development in BALB/c.IL-6 −/− mice. Rudikoff and co-workers showed that this was effected by the Abl tyrosine kinase by virtue of constitutively activating Stat3, a key component in the IL-6 signaling cascade. 31 These results did not only strengthen the concept that IL-6 signaling is a critical requirement for all forms of BALB/c plasmacytomagenesis, they also suggested that the combination of constitutive IL-6 and Myc expression suffices to initiate plasmacytoma development on the background of genetic susceptibility. 2, 32 We hypothesize it may not matter if the combined 'IL-6 plus Myc effect' is delivered by a retrovirus, like the Abl/Myc virus, or accomplished by the transgenic expression of IL-6 in B/plasma cells that harbor c-myc-activating chromosomal translocations. If this prediction is correct, plasmacytomagenesis should occur spontaneously in lymphoid tissues of BALB/c.IL-6 mice.
The possibility that the 5Ј-C/c-myc + clones, or at least a fraction of them, may be the precursors of plasmacytomas in BALB/c.IL-6 mice, raised two immediate questions concerning the neoplastic nature (fully transformed, premalignant, nonmalignant?) and differentation stage of these clones. Our observation that the 5Ј-C/c-myc + clones were detected in tissues that were heavily infiltrated by plasma cells (plasmacytosis) seemed to be most compatible with the proposition that the clones were of plasmacytic nature. However, Ohno et al recently used IL-6 transgenic hyperplastic lymph Leukemia nodes to separate immunoglobulin-expressing cells (B cells) from non-expressing cells (plasma cells), transferred them individually into syngeneic recipients, but were only able to induce donor-type plasmacytomas upon transfer of B cells. These authors concluded that 'immature/mature' B cells, but not plasma cells, are the plasmacytoma precursors. 7 One possibility to reconcile this conclusion with our histological observations is that 5Ј-C/c-myc rearrangements occur in mature B cells that may constitute the transplantable plasmacytoma precursor pool that resides together with normal B cells as a minority population in plasmacytotic lymph nodes, but that these B cells are at the same time relentlessly stimulated by IL-6 to proliferate in situ and differentiate into plasma cells. This hypothesis would explain the presence of the massive plasmacytotic infiltrates that are typical for lymphoid tissues of BALB/c.IL-6 mice. It would furthermore predict that clonotypic 5Ј-C/c-myc rearrangements may occur in lymphoid tissues throughout the mature B cell lineage, including IgM-expressing lymphocytes, lymphoplasmacytoid cells, plasma blasts, and plasma cells.
An interesting difference between the 5Ј-C/c-myc + clones residing in normal and IL-6 transgenic BALB/c mice was noted when the distributions of recombination breaksites in c-myc were compared. The breaksites occurred upstream of exon 1 of c-myc (class II translocations according to Cory 8 ) in four of five (80%) plasmacytoma precursor clones in normal BALB/c mice, 1 but within exon 1 or downstream of it (class I translocations according to Cory) in 14 of 15 (93%) clones in BALB/c.IL-6 mice. This difference is currently not explained, but may indicate that the great majority of clones in strain BALB/c.IL-6 were innocent by-standers that did not belong to the putative plasmacytoma precursor pool. An alternative explanation, favored by us, postulates that class II translocations are not preferred at all in the IL-6 transgenic plasmacytoma precursor pool. This view is based on recent findings by Kiuchi and co-workers 18 who showed that IL-6 is able and sufficient to activate c-myc in B cells, and further demonstrated that this activation is mediated by Stat3 via a binding site that overlaps with an E2F site at the beginning of exon 1 of c-myc. It is intriguing that in all but one of the IL-6 transgenic clones, the Stat3 binding site has been allocated to the reciprocal product of translocation, Chr T(15;12), which is presumably irrelevant for oncogenesis (see Figure 2 , in which the Stat3 site is indicated by an asterisk between the two major promoters of c-myc). In this situation, IL-6 must be unable to contribute to the transcriptional activation of the rearranged c-myc gene, since this takes place on Chr T(12;15) under the control of the immunoglobulin heavy-chain gene enhancers located 3Ј of C␣. 33 If the Stat3 site remained on Chr T(12;15) and led there to the co-activation of c-myc by IL-6 and the 3Ј-C␣ enhancers, and if this co-activation resulted in excessively high c-myc transcript levels that were not tolerated by B/plasma cells but induced them to undergo apoptosis instead, 34 then it could be argued that the apparent preference of class I translocations in BALB/c.IL-6 mice reflected a selection process in vivo that favored class I translocated clones (Stat3 site is on Chr T [15;12] ), but discriminated against class II translocated clones (Stat3 site is on Chr T [12;15] ). This hypothesis has not been proven.
In conclusion, the present study has revealed that the cooperation of three pathogenetic factors in one mouse, ie constitutive IL-6 signaling (by transgenic expression of IL-6), activation of c-myc (by chromosomal translocation), and plasmacytoma susceptibility alleles (genotype of BALB/c), suffices to promote the growth and/or survival of 5Ј-C/c-myc + clones,
Figure 3
Comparison of plasmacytomagenesis in conventional and IL-6 transgenic BALB/c mice. IL-6 may facilitate plasmacytoma development at various stages of tumor development, but its apparent ability to promote 5Ј-C/c-myc + clones, the putative plasmacytoma precursors, is the focus here. The biological properties of the cell in which the genetic exchange between 5Ј-C and c-myc occurred have not been established, yet the mature IgM-expressing B lymphocyte that is in the process of isotype switching (indicated below the pictographs of the mice) is a plausible candidate in both strains. These cells may readily differentiate into 5Ј-C/c-myc + plasma cells in situ, as indicated in the third paragraph of the Discussion section. 5Ј-C/c-myc + clones were found in inflammatory granulomata of pristane-primed BALB/c mice (13% incidence) and secondary lymphoid tissues of untreated BALB/c.IL-6 mice (48% incidence), as indicated at the top. The molecular schemes in the center illustrate that the majority of the IL-6 transgenic 5Ј-C/c-myc + clones preferred c-myc rearrangements of class I, whereas most plasmacytoma precursors in BALB/c mice preferred c-myc rearrangements of class II. The reason for this difference is not presently known, but two explanations are offered in the fourth paragraph of the Discussion. Furthermore, it has not been established whether the Chr T(12;15) translocation breakpoint regions in IL-6 transgenic 5Ј-C/c-myc + clones are subject to 'remodeling' by aberrant isotype switching in the same way as this occurs in plasmacytoma precursors in normal BALB/c mice (indicated by the question mark to the lower left above the arrow). In normal BALB/c mice, remodeling has been shown to convert original 5Ј-C/c-myc recombinations into secondary 5Ј-C␣/c-myc recombinations, thereby approximating the rearranged c-myc gene over a 180-kb distance to the powerful 3Ј-C␣ enhancers (depicted by the filled diamond labeled 'E'). This conversion event is illustrated by the two dashed lines that join S with S␣ (symbolized by open circles 5Ј to C and C␣, which are depicted by labeled rectangles). Finally, it remains to be shown whether IL-6 transgenic plasmacytomas will display the same phenotypic preferences as their counterparts in conventional BALB/c mice (see the question mark to the lower left below the arrow). That is, approximately 60% of pristane-induced T (12;15) + BALB/c plasmacytomas have been shown to produce IgA, and ෂ85% of them utilize rearrangements between c-myc and C␣ on Chr T(12;15) (indicated at the bottom, right). The prevalence of this phenotype in BALB/c.IL-6 plasmacytomas will be evaluated once the tumors become available.
the putative plasmacytoma precursors. The observation that such clones appeared to develop spontaneously in the secondary lymphoid tissues of untreated BALB/c.IL-6 mice defined a major distinction to conventional BALB/c mice, since the latter required i.p. priming with inflammatory agents (eg pristane) to support the development of 5Ј-C/c-myc + clones in an artificial environment, the granulomatous tissue. Future experiments will be aimed at exploiting the apparent prevalence and expansion of 5Ј-C/c-myc + clones in IL-6 transgenic BALB/c mice to gain further insights into the biological properties of the plasmacytoma precursor, a longstanding and enigmatic problem in mouse plasmacytoma research. Additional studies will be conducted to test the hypothesis that plasmacytomas may develop spontaneously in BALB/c.IL-6 mice (see second paragraph of the Discussion section), and to clarify the role if any of 'translocation remodeling' during IL-6 facilitated plasmacytomagenesis. Finally, the prevalence of the 5Ј-C␣/c-myc
+
IgA
+ phenotype, the characteristic phenotype of conventional BALB/c plasmacytomas, will have to be determined in IL-6 transgenic plas-macytomas once they become available (see Figure 3 for details).
